Navigation Links
ANI Pharmaceuticals Acquires 31 Generic Drug Products from Teva Pharmaceuticals
Date:12/26/2013

BAUDETTE, Minn., Dec. 26, 2013 /PRNewswire/ -- ANI Pharmaceuticals, Inc. (NASDAQ: ANIP), an emerging generic pharmaceutical company, today announced that it has acquired 31 previously marketed generic drug products from Teva Pharmaceuticals for $12.5 million in cash and a percentage of future gross profits from product sales.  The acquisition includes 20 solid-oral immediate release products, 4 extended release products and 7 liquid products.  ANI will begin work immediately on transferring these products into its manufacturing facilities in anticipation of product launches beginning in the fourth quarter of 2014.  All of these products have been previously approved by FDA as abbreviated new drug applications (ANDAs).  The total current annual market for these products is $860 million per IMS Health. 

Arthur S. Przybyl, President and CEO of ANI Pharmaceuticals, stated, "This acquisition is a significant opportunity for ANI to expand our generic product portfolio beyond our current seven marketed products.  When launched, these products will strengthen our business by growing our revenue base and leveraging our manufacturing capabilities.  We are excited that this transaction extends the ANI-Teva relationship beyond the existing generic testosterone gel partnership."

Robert W. Schrepfer, VP of New Business Development, commented, "This transaction demonstrates ANI's commitment to diversify our marketed product portfolio and supplement our internal product development efforts through a business development plan that includes partnerships, acquisitions and in-licensing." 

About ANI

ANI is an integrated specialty pharmaceutical company developing, manufacturing, and marketing branded and generic prescription pharmaceuticals. In two facilities with combined manufacturing, packaging and laboratory capacity totaling 173,000 square feet, ANI manufactures oral solid dose products, as well as liquids and topicals, including narcotics and those that must be manufactured in a fully contained environment due to their potency and/or toxicity. ANI also performs contract manufacturing for other pharmaceutical companies. Over the last two years ANI has launched three new products and has twelve products in development. ANI's targeted areas of product development include narcotics, anti-cancers and hormones (potent compounds), and extended release niche generic product opportunities. ANI's other products include an FDA-approved testosterone gel, which is licensed to Teva Pharmaceuticals USA. For more information please visit our website www.anipharmaceuticals.com.

Forward-Looking Statements

To the extent any statements made in this release deal with information that is not historical, these are forward-looking statements under the Private Securities Litigation Reform Act of 1995. Such statements include, but are not limited to, statements about the potential benefits of the merger, the combined company's plans, objectives, expectations and intentions with respect to future operations and products, the anticipated financial position, operating results and growth prospects of the combined company and other statements that are not historical in nature, particularly those that utilize terminology such as "anticipates," "will," "expects," "plans," "potential," "future," "believes," "intends," "continue," other words of similar meaning, derivations of such words and the use of future dates. Forward-looking statements by their nature address matters that are, to different degrees, uncertain. Uncertainties and risks may cause the combined company's actual results to be materially different than those expressed in or implied by such forward-looking statements. Uncertainties and risks include the risk that the Company may in the future be required to seek FDA approval for its unapproved products or withdraw such products from the market; the Company may fail to meet NASDAQ listing requirements; general business and economic conditions; the Company's need for and ability to obtain additional financing; the difficulty of developing pharmaceutical products, obtaining regulatory and other approvals and achieving market acceptance; and the marketing success of the Company's licensees or sublicensees. More detailed information on these and additional factors that could affect the Company's actual results are described in the Company's filings with the Securities and Exchange Commission, including its most recent annual report on Form 10-K and this quarterly report on Form 10-Q, as well as its proxy statement/prospectus, filed with the Securities and Exchange Commission on May 8, 2013. All forward-looking statements in this release speak only as of the date made and are based on the Company's current beliefs and expectations. The Company undertakes no obligation to update or revise any forward-looking statement, whether as a result of new information, future events or otherwise.

Contact:
ANI Pharmaceuticals
218-634-3500


'/>"/>
SOURCE ANI Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. New Appointments, and Share Price Movements - Research Report on Humana, Illumina, Edwards Lifesciences, Aegerion Pharmaceuticals, and CytRx
2. Taiwan Spends a High Percentage of its Healthcare Budget on Pharmaceuticals, but Second Generation Healthcare Reform is Transforming the Market Landscape
3. Valeant Pharmaceuticals To Present At Industry Conferences
4. Positive Trial Results, Completed Acquisitions, and Clearances - Research Report on Dyax, IPC, Array BioPharma, Lexicon Pharmaceuticals, and Wright Medical
5. Updated Financial Standings, Company Announcements, and Customer-Centered Suggestions - Research Report on Perrigo, Thermo Fisher, DaVita, United Therapeutics, and Keryx Biopharmaceuticals
6. Jazz Pharmaceuticals And Gentium S.p.A. Announce Agreement For Jazz Pharmaceuticals To Acquire Gentium For $57.00 Per Share
7. Educational Grant Awarded to Winner of Ferring Pharmaceuticals Inaugural Heart to Heart Video Contest
8. Prolong Pharmaceuticals Adds Industry Veteran Ronald Jubin To Executive Management Team
9. Avista Capital Partners Announces a Majority Investment in Vertical Pharmaceuticals and Trigen Laboratories
10. Valeant Pharmaceuticals Agrees to Acquire Solta Medical for $2.92 Per Share in Cash
11. Everett Laboratories Acquires Quinnova Pharmaceuticals to Diversify U.S. Pharmaceutical Presence
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/7/2017)... Ind. , Sept. 7, 2017  Zimmer Biomet ... in musculoskeletal healthcare, today announced that it will be ... Global Healthcare Conference at the Grand Hyatt hotel in ... 11, 2017 at 11:40 a.m. Eastern Time. ... via Zimmer Biomet,s Investor Relations website at http://investor.zimmerbiomet.com ...
(Date:9/6/2017)... Sept. 6, 2017 NeuroRx, a clinical stage biopharma ... and Behavior (ASIB), has been granted Fast Track status by ... of NRX-100 (ketamine HCl) followed by NRX-101 (D-cycloserine + lurasidone). ... trial of this sequential therapy targeting patients who are admitted ... ...
(Date:9/5/2017)... LONDON , Sept. 5, 2017  Just 18 ... Valid Insight is pleased to announce the appointment of ... Tammy Wynne , Dominic Jones-Phillips and ... from industry. ... a team of market access writers. She has over ...
Breaking Medicine Technology:
(Date:9/21/2017)... (PRWEB) , ... September 21, 2017 , ... Japanese Zen ... Yoga Mat Revolution” on 6th, 7th and 8th October at Miranda Kuo Gallery on ... mat art pieces, such as Zen Kodo mat. Wanderlust , one of the ...
(Date:9/21/2017)... Boulder, CO (PRWEB) , ... September 21, 2017 ... ... Education Interview of the Month, Lewis and Clark College Emeritus Professor of Education ... Associate Faith Boninger, co-author of Asleep at the Switch: Schoolhouse Commercialism, Privacy, ...
(Date:9/20/2017)... ... September 20, 2017 , ... ... voice for people who have kidney disease. The theme “Describe a positive decision ... stories. Entrants needed to meet only one qualification— to have been diagnosed ...
(Date:9/20/2017)... ... September 20, 2017 , ... Announced ... Aligner clinical and commercial support services market) has entered into an agreement on ... Australia. , The PGSD is the first private Dental School to launch ...
(Date:9/20/2017)... ... September 20, 2017 , ... The Honey Pot ... Vaginas.” The goal is to ignite conversation via social media and word-of-mouth regarding ... brand has declared September “Humans with Vaginas” month, releasing a video celebrating the ...
Breaking Medicine News(10 mins):